Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme

Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor. Despite aggressive multimodality treatment it remains one of the most challenging and intractable cancers (1]. While current standard of care treatment for GBM is maximal safe surgical resection, systemic chemotherapy wi...

Full description

Bibliographic Details
Main Authors: Christopher Chin, Emma S. Lunking, Macarena de la Fuente, Nagi G. Ayad
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Oncology
Subjects:
glioblastoma
immunotherapeutic
clinical trial
epigenetic
long non coding RNA
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00521/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00521/full

Similar Items